GPCR250117P32500
- 5.80
- 0.000.00%
Structure Therapeutics Newsroom
H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80
Promising Potential of Structure Therapeutics' ACCG-2671 Drives Buy Rating
Buy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment Platform
Express News | Shares of Viking Therapeutics up 4.2%, Amgen up 1%
Express News | Weight Loss Drug Developers Rise Intraday Trading After Novo Nordisk's Obesity Drug Cagrisema Achieves Lower Weight Loss Than Expected
Structure Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Hims & Hers Shares Tumble as FDA Resolves Obesity Drug Shortage
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy From Piper Sandler
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
Express News | Shares of Structure Therapeutics Fall 7.2%, Viking Therapeutics Fall 7.9%
Express News | Shares of Some Obesity Drug Developers Fall After Merck Signs up to $2 Bln Deal for Oral Obesity Drug
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Promising Prospects for Structure Therapeutics: Advancements in Amylin Drug Development and Strategic Positioning
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Raises Target Price to $91
Buy Rating on Structure Therapeutics: Promising Developments in GPCR's Oral Amylin-Based Drug and Broad Obesity Treatment Pipeline
Structure Therapeutics Advances Obesity Treatment Candidate
Express News | Structure Therapeutics Inc - Phase 1 Study of Accg-2671 Expected to Start by Year End 2025